【藥品庫存】 藥品安全警訊 (藥品回收)：本品經食藥署公告緊急回收，經詢感染控制部，回收停用期間請以本院第三代口服頭孢子菌素抗生素取代，更新日期：2020/5/22。

Cephalosporins類 (二代) Pharyngitis/Tonsillitis, Acute Bacterial Otitis Media, Acute Bacterial Maxillary Sinusitis, Acute Bacterial Exacerbations of Chronic Bronchitis, Uncomplicated Skin and Skin-Structure Infections, Uncomplicated Urinary Tract Infections, Uncomplicated Gonorrhea, Early Lyme Disease. (US FDA approved) Repaglinide is an oral agent of the meglitinide class used for treating noninsulin dependent diabetes mellitus.

Cefuroxime sodium is a semisynthetic, broad-spectrum, cephalosporin antibiotic, which is highly stable to deactivation by certain gram-negative beta-lactamases.

Protein binding: approximately 50%. Renal: approximately 89% over 8 h. Dialyzable: yes (hemodialysis); yes (peritoneal dialysis). Elimination Half Life: ~80 min.

Hypersensitivity to cephalosporin antibiotics

B (FDA)

AAP: Maternal medication usually compatible with breastfeeding.

Eosinophilia 1%; Diarrhea 4%; Nausea/Vomiting 3%; Transient elevation in AST 2%; Transient elevation in ALT 2%; Transient elevation in LDH 1%

Pharyngitis/tonsillitis (mild to moderate):　250 mg every 12 hours 10 days; Acute bacterial maxillary sinusitis (mild to moderate) 250 mg every 12 hours 10 days; Acute bacterial exacerbations of chronic bronchitis (mild to moderate): 250 mg or 500 mg every 12 hours 10 days. Uncomplicated skin and skin-structure infections: 250 mg or 500 mg every 12 hours 10 days. Uncomplicated urinary tract infections: 250 mg every 12 hours 7 to 10 days; Uncomplicated gonorrhea: 1000 mg single dose; Early Lyme disease: 500 mg every 12 hours 20 days. (US FDA approved)